Zogenix (ZGNX) Tops Q4 EPS by 33c

Zogenix (NASDAQ: ZGNX) reported Q4 EPS of ($0.36), $0.33 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $6.39 million.

2016 Financial Guidance

Below is the Company’s financial guidance for the full year 2016.

• Research and development expenses are expected to be $54-59 million, reflecting initiation and ramp-up of ZX008 clinical studies;
• Selling, general and administrative expenses are expected to be $25-27 million; and
• Contract manufacturing revenue from the supply of Sumavel DosePro to Endo is expected at a low single-digit markup over cost of contract manufacturing.

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Southland Holdings (SLND) Misses Q2 EPS by 122c
• ITG (ITG) Tops Q2 EPS by 1c